Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients

Therapeutic Drug Monitoring

Volumn 32, Issue 6, 2010, Pages 762-766

  Ramasamy, Kesavan ^a   Narayan, Sunil K ^b   Shewade, Deepak Gopal ^a   Chandrasekaran, Adithan ^a  

^a Department of Pharmacology   (India)

^b JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

CYP2C9; epileptics; free plasma phenytoin concentration; phenytoin (PHT); undernourishment

Indexed keywords

ALBUMIN; ANTICONVULSIVE AGENT; CYTOCHROME P450 2C9; GENOMIC DNA; PHENOBARBITAL; PHENYTOIN;

ADULT; ALBUMIN BLOOD LEVEL; ANTICONVULSANT THERAPY; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; EPILEPSY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; MALNUTRITION; NUTRITIONAL STATUS; PHARMACOGENETICS; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; ALLELES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; EPILEPSY; FEMALE; GENOTYPE; HUMANS; MALE; MALNUTRITION; PHENYTOIN; POLYMORPHISM, GENETIC;

EID: 78649336148     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181fa97cc     Document Type: Article

References (38)

1. Rimmer EM, Buss DC, Routledge PA, et al. Should we routinely measure free plasma phenytoin concentration? Br J Clin Pharmacol. 1984;17:99-102.
2. Mamiya K, Yukawa E, Matsumoto T, et al. Synergistic effect of valproate coadministration and hypoalbuminemia on the serum-free phenytoin concentration in patients with severe motor and intellectual disabilities. Clin Neuropharmacol. 2002;25:230-233.
3. Lindow J, Wijdicks EF. Phenytoin toxicity associated with hypoalbumi-nemia in critically ill patients. Chest. 1994;105:602-604.
4. Hong JM, Choi YC, Kim WJ. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Yonsei Med J. 2009;50:517-520.
5. Toler SM, Wilkerson MA, Porter WH, et al. Severe phenytoin intoxication as a result of altered protein binding in AIDS. DICP. 1990;24:698-700.
6. Kemper EM, Van Kan HJ, Speelman P, et al. Severe phenytoin intoxication in patients with hypoalbuminaemia [in Dutch]. Ned Tijdschr Geneeskd. 2007;151:138-141.
7. Campbell TC, Hayes JR. Role of nutrition in the drug-metabolizing enzyme system. Pharmacol Rev. 1974;26:171-197.
8. Rumack BH, Holtzman J, Chase HP. Hepatic drug metabolism and protein malnutrition. J Pharmacol Exp Ther. 1973;186:441-446.
9. Lee JH, Suh OK, Lee MG. Pharmacokinetic changes in drugs during protein-calorie malnutrition: correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes. Arch Pharm Res. 2004;27:693-712.
10. Mason P. Undernutrition in hospital causes and consequences. Hospital Pharmacist. 2006;13:353-358.
11. Mao ZL, Tam YK, Coutts RT. Effect of protein and calorie malnutrition on drug metabolism in rat in vitro. J Pharm Pharm Sci. 2006;9:60-70.
12. Zhang W, Parentau H, Greenly RL, et al. Effect of protein-calorie malnutrition on cytochromes P450 and glutathione S-transferase. Eur J Drug Metab Pharmacokinet. 1999;24:141-147.
13. Cho MK, Kim YG, Lee MG, et al. Suppression of rat hepatic cytochrome P450s by protein-calorie malnutrition: complete or partial restoration by cysteine or methionine supplementation. Arch Biochem Biophys. 1999; 372:150-158.
14. Lee PG, Struve MF, Bezerra JA, et al. Effects of protein malnutrition on liver cytochrome P45Os. Nutr Res. 1997;17:1577-1587.
15. Hashimoto Y, Otsuki Y, Odani A, et al. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol Pharm Bull. 1996;19:1103-1105.
16. Aynacioglu AS, Brockmoller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional releVance for phenytoin. Br J Clin Pharmacol. 1999;48:409-415.
17. Mamiya K, Ieiri I, Shimamoto J, et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia. 1998;39:1317-1323.
18. Kerb R, Aynacioglu AS, Brockmoller J, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 2001;1:204-210.
19. Odani A, Hashimoto Y, Otsuki Y, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther. 1997;62:287-292.
20. Takanashi K, Tainaka H, Kobayashi K, et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics. 2000;10:95-104.
21. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994;4:39-42.
22. Rettie AE, Haining RL, Bajpai M, et al. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 1999;35:253-255.
23. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001;11:803-808.
24. Lee AY, Kim MJ, Chey WY, et al. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2004;60:155-159.
25. Ninomiya H, Mamiya K, Matsuo S, et al. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit. 2000;22:230-232.
26. Hennessy S, Leonard CE, Freeman CP, et al. CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol. 2009;49:1483-1487.
27. Citerio G, Nobili A, Airoldi L, et al. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction. Neurology. 2003;60:1395-1396.
28. McCluggage LK, Voils SA, Bullock MR. Phenytoin toxicity due to genetic polymorphism. Neurocrit Care. 2009;10:222-224.
29. Ferro-Luzzi A, Petracchi C, Kuriyan R, et al. Basal metabolism of weight-stable chronically undernourished men and women: lack of metabolic adaptation and ethnic differences. Am J Clin Nutr. 1997;66:1086-1093.
30. KesaVan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol. 2010;66:689-696.
31. Kutt H, Kokenge R, Winters W, et al. Diphenylhydantoin metabolism, blood levels, and toxicity. Arch Neurol. 1964;11:642-648.
32. Troupin AS, Ojemann LM. Paradoxical intoxication-a complication of anticonvulsant administration. Epilepsia. 1975;16:753-758.
33. Adithan C, Gerard N, Vasu S, et al. Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol. 2003;59:707-709.
34. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U.S.A. 1977;74:5463-5467.
35. Lin CJ, Yen MF, Hu OY, et al. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy. Pharmacotherapy. 2008;28:35-41.
36. Loscher W. Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. J Pharmacol Exp Ther. 1978;204:255-261.
37. Gerson B, Bell F, Chan S. Antiepileptic agents-primidone, phenobar-bital, phenytoin, and carbamazepine by reversed-phase liquid chroma-tography. Clin Chem. 1984;30:105-108.
38. Jose R, Chandrasekaran A, Sam SS, et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol. 2005;19:101-105.